Information for Tirzepatide
Tirzepatide was developed to fight type 2 diabetes, but has additionally been shown to protect the cardiovascular system and act as a potent weight loss agent. Tirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality as well.
Research Certificates of Analysis
17.74mg
Task #42383
Batch #04072024
04/12/2024
30.25mg
Task #42388
Batch #04162024
04/23/2024
34.15mg
Task #48136
Batch #08022024
08/02/2024
30.02mg
Task #48957
Batch #09122024
09/12/2024
12.06mg
Task #46312
Batch FTIR-0001
08/01/2024
GMP Certificates of Analysis
15.2mg
Batch #PKTZ15924
09/10/2024
30.1mg
Batch #PKTZ30924
09/10/2024
Tirzepatide Peptide Structure
Source: PubChem
Amino Acid Sequence: YE-Aib-GTFTSDYSI-Aib-LDKIAQ (C20 fatty acid) AFVQWLIAGGPSSGAPPPS
Note: Aib is a non-coded (non-proteinogenic) amino acid – H2H-C(CH3)2-COOH
Molecular Formula: C225H348N48O68
Molecular Weight: 4813.527 g/mol
PubChem CID: 156588324
CAS Number: 2023788-19-2
Synonyms: P1206, LY3298176
What Is Tirzepatide?
Regulates blood glucose levels1
Encourages weight loss in patients with type 2 diabetes1
Enhances insulin release and sensitivity2
Improves function of beta cells2
Decreases level of LDL cholesterol3
Research Studies
- Farzam, K., & Patel, P. (2024, February 20). Tirzepatide. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK585056/#:~:text=Tirzepatide%20is%20a%20dual%20agonist,1%20medications%20such%20as%20semaglutide
- Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2020). Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in Type 2 diabetes. the Journal of Clinical Endocrinology and Metabolism/Journal of Clinical Endocrinology & Metabolism, 106(2), 388–396. https://doi.org/10.1210/clinem/dgaa863
- Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020). The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 22(12), 2451–2459. https://doi.org/10.1111/dom.14174
Product Usage
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.
